Phase II study of Erlotinib Plus Bevacizumab in patients with advanced Non-squamous and Non- Small Cell Lung Cancer not harboring EGFR mutation who failed to prior treatment (TAILORED-2 study)
Phase 2
Recruiting
- Conditions
- on-Small Cell Lung Cancer
- Registration Number
- JPRN-UMIN000006459
- Lead Sponsor
- Kyushu University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 38
Inclusion Criteria
Not provided
Exclusion Criteria
1)Squamous cell carcinoma 2)Interstitial pneumonia or pulmonary fibrosis on chest CT scans 3) i)Brain metastasis expected bleeding ii)Patients with untreated Brain metastasis 4)Undergoing prior EGFR-TKI treatment 5)Active severe comorbidity disease. 6)History of hemoptysis 7)Uncontrollable hypertension 8)History of gastrointenstinal perforation or diverticulitis or fistula 9)Scheduled operation 10)History of grave drug allergic reaction. 11)Active concomitant malignancy 12)Pregnant or breast-feeding females 13)Inappropriate patients for this study judged by the physicians
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression Free Survival
- Secondary Outcome Measures
Name Time Method Response Rate Disease Control Rate Overall Survival Safety